Media

Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome

Fusion Pharmaceuticals Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility

Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases

Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021

Nordic Nanovector ASA: Results for the First Quarter 2021

Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Invitation to presentation of the Q1 2021 results